Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 1/2004

01-09-2004 | Original Review Article

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis

Author: Dr Deborah P. Lubeck

Published in: PharmacoEconomics | Special Issue 1/2004

Login to get access

Abstract

Patients with rheumatoid arthritis (RA) face considerable physical, social and emotional disabilities. In this chronic disease, for which a cure is not yet available, improving patients’ health-related quality of life (HRQoL) is of the utmost concern, particularly as the use of long-term and potentially toxic therapy increases. Early HRQoL outcome measures in RA focused on physical functioning, but the social and emotional aspects of the disease are now increasingly important. Thus, several generic and RA-specific HRQoL instruments have been developed, but no one tool covers all areas of HRQoL that affect the patient with RA. For this reason, a combination of generic and disease-specific tools is currently recommended for RA clinical trials.
Literature
1.
Anonymous. The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD. Am J Manag Care 1999; 5 Suppl. 14: S852–9; discussion S866-9
2.
Harris Jr ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322 (18): 1277–89PubMedCrossRef
3.
Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24 (1): 43–8PubMed
4.
WHO, The First Ten Years of the World Health Organization. 1958, Geneva: World Health Organization
5.
Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991; 18 (9): 1298–306PubMed
6.
Callahan LF, Brooks RH, Summey JA, Pincus T. Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis Rheum 1987; 30 (6): 630–6PubMedCrossRef
7.
MacKinnon JR, Avison WR, McCain GA. Pain and functional limitations in individuals with rheumatoid arthritis. Int J Rehabil Res 1994; 17 (1): 49–59PubMedCrossRef
8.
Kazis LE, Meenan RF, Anderson JJ. Pain in the rheumatic diseases. Investigation of a key health status component. Arthritis Rheum 1983; 26 (8): 1017–22PubMedCrossRef
9.
Nichol MB, Harada AS. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review. Pharmacoeconomics 1999; 16 (5 Pt 1): 433–48PubMedCrossRef
10.
Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35 (5): 498–502PubMedCrossRef
11.
Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989; 16 (7): 867–84PubMed
12.
Yelin E. Arthritis. The cumulative impact of a common chronic condition. Arthritis Rheum 1992; 35 (5): 489–97PubMed
13.
14.
Katz PP, Yelin E. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993; 20 (5): 790–6PubMed
15.
Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995; 22 (4): 639–43PubMed
16.
Fifield J, McQuillan J, Tennen H, et al. History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Ann Behav Med 2001; 23 (1): 34–41PubMedCrossRef
17.
Singh G, Lingala B, Bennett M, Wanke L, Singh A. Epidemiology of fatigue in rheumatoid arthritis: prevalence and clinical correlates. Presented at EULAR 2003, Lisbon, Portugal
18.
Singh G, Lingala B, Bennett M, Wanke L, Singh A. Fatigue in rheumatoid arthritis: significant correlation with direct medical costs and missed days of work. Presented at EULAR 2003, Lisbon, Portugal
19.
Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23 (8): 1407–17PubMed
20.
Lorish CD, Abraham N, Austin J, Bradley LA, Alarcon GS. Disease and psychosocial factors related to physical functioning in rheumatoid arthritis. J Rheumatol 1991; 18 (8): 1150–7PubMed
21.
Belza BL, Henke CJ, Yelin EH, Epstein WV, Gillis CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42 (2): 93–9PubMedCrossRef
22.
Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998; 37 (10): 1042–6PubMedCrossRef
23.
Smith TW, Peck JR, Ward JR. Helplessness and depression in rheumatoid arthritis. Health Psychol 1990; 9 (4): 377–89PubMedCrossRef
24.
Callahan LF, Cordray DS, Wells G, Pincus T. Formal education and five-year mortality in rheumatoid arthritis: Mediation by helplessness scale scores. Arthritis Care Res 1996; 9 (6): 463–72PubMedCrossRef
25.
Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27 (2): 283–303PubMedCrossRef
26.
Gabriel S, Crowson C, O’Fallon W. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26: 2529–33PubMed
27.
Verbrugge LM, Gates DM, Ike RW. Risk factors for disability among U.S. adults with arthritis. J Clin Epidemiol 1991; 44 (2): 167–82PubMedCrossRef
28.
Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36 (6): 729–40PubMedCrossRef
29.
Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A. A comparison of the sensitivity to change of several health status instruments in rheumatoid arthritis. J Rheumatol 1993; 20 (3): 429–36PubMed
30.
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118 (8): 622–9PubMed
31.
Guyatt GH, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40 (2): 171–8PubMedCrossRef
32.
Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 Suppl. 3: S217–32PubMedCrossRef
33.
Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ 1986; 134 (8): 889–95PubMed
34.
Ware Jr JE. The status of health assessment 1994. Annu Rev Public Health 1995; (16): 327–54
35.
Cheah SY, Clark C, Goldberg L, Li Wan Po A, Phillips R. Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. J Clin Pharm Ther 1996; 21 (5): 297–316PubMedCrossRef
36.
de Jong Z, van der Heijde D, McKenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 1997; 36 (8): 878–83PubMedCrossRef
37.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23 (2): 137–45PubMedCrossRef
38.
Bruce B, Fries JF. The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30 (1): 167–78PubMed
39.
Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures’ responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995; 38 (11): 1568–80PubMedCrossRef
40.
Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25 (2): 206–9PubMedCrossRef
41.
Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 1992; 19 (12): 1906–11PubMed
42.
Wolfe F, Pincus T. Standard self-report questionnaires in routine clinical and research practice—an opportunity for patients and rheumatologists. J Rheumatol 1991; 18 (5): 643–6PubMed
43.
Ramey DR, Raynauld JP, Fries JF. The Health Assessment Questionnaire 1992: status and review. Arthritis Care Res 1992; 5 (3): 119–29PubMedCrossRef
44.
Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9 (5): 789–93PubMed
45.
Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002; 8 (3): 231–40PubMed
46.
Pincus T, Summey JA, Soraci Jr SA, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26 (11): 1346–53PubMedCrossRef
47.
Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35 (273): 185–8PubMed
48.
Essink-Bot M-L, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures: The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument. Med Care 1997; 35 (5): 522–37PubMedCrossRef
49.
Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 1981; 15 (3 Pt 1): 221–9
50.
Jenkinson C, Fitzpatrick R, Argyle M. The Nottingham Health Profile: an analysis of its sensitivity in differentiating illness groups. Soc Sci Med 1988; 27 (12): 1411–4PubMedCrossRef
51.
Wells G, Boers M, Shea B, et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology. J Rheumatol 1999; 26 (1): 217–21PubMed
52.
Houssien DA, McKenna SP, Scott DL. The Nottingham Health Profile as a measure of disease activity and outcome in rheumatoid arthritis. Br J Rheumatol 1997; 36 (1): 69–73PubMedCrossRef
53.
Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305 (6846): 160–4PubMedCrossRef
54.
Carter WB, Bobbitt RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. Health Serv Res 1976; 11 (4): 516–28PubMed
55.
Sullivan M, Ahlmen M, Bjelle A. Health status assessment in rheumatoid arthritis. I. Further work on the validity of the Sickness Impact Profile. J Rheumatol 1990; 17 (4): 439–47PubMed
56.
MacKenzie CR, Charlson ME, DiGioia D, Kelley K. Can the Sickness Impact Profile measure change? An example of scale assessment. J Chronic Dis 1986; 39 (6): 429–38PubMedCrossRef
57.
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473–83PubMedCrossRef
58.
McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32 (1): 40–66PubMedCrossRef
59.
Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. J Rheumatol 1997; 24 (10): 1910–5PubMed
60.
Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br J Rheumatol 1997; 36 (4): 463–9PubMedCrossRef
61.
Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (7): 1478–87PubMedCrossRef
62.
Singh A, Wanke LA, Parasuraman TV, Lubeck D. Reliability and validity of SF-36 vitality scale in measuring vitality of methotrexate-naive patients with early, active rheumatoid arthritis. Presented at American College of Rheumatology 2002
63.
van Agt HM, Essink-Bot M-L, Krabbe PF, Bonsel GJ. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med 1994; 39 (11): 1537–44PubMedCrossRef
64.
Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2 (3): 169–80PubMedCrossRef
65.
The EuroQoL Group. EuroQol — a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16 (3): 199–208
66.
Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQol—a generic health status instrument—in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 1994; 33 (7): 655–62PubMedCrossRef
67.
Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997; 36 (7): 786–93PubMedCrossRef
68.
Macran S, Weatherly H, Kind P. Measuring population health: a comparison of three generic health status measures. Med Care 2003; 41 (2): 218–31PubMed
69.
Kaplan RM, Anderson JP, Wu AW, Mathews WC, Kozin F, Orenstein D. The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis. Med Care 1989; 27 Suppl. 3: S27–43PubMedCrossRef
70.
Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995; 7 (6): 490–502PubMedCrossRef
71.
Bombardier C and Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control Clin Trials 1991; 12 Suppl. 4: 243S–56SPubMedCrossRef
72.
Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003; 56 (4): 317–25PubMedCrossRef
73.
Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The Arthritis Impact Measurement Scales. Arthritis Rheum 1980; 23 (2): 146–52PubMedCrossRef
74.
Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Further investigations of a health status measure. Arthritis Rheum 1982; 25 (9): 1048–53PubMedCrossRef
75.
Anderson JJ, Firschein HE, Meenan RF. Sensitivity of a health status measure to short-term clinical changes in arthritis. Arthritis Rheum 1989; 32 (7): 844–50PubMed
76.
Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985; 28 (5): 542–7PubMedCrossRef
77.
Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992; 35 (1): 1–10PubMedCrossRef
78.
Pouchot J, Guillemin F, Coste J, Bregeon C, Sany J. Validity, reliability, and sensitivity to change of a French version of the Arthritis Impact Measurement Scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23 (1): 52–60PubMed
79.
Archenholtz B, Bjelle A. Reliability, validity, and sensitivity of a Swedish version of the revised and expanded Arthritis Impact Measurement Scales (AIMS2). J Rheumatol 1997; 24 (7): 1370–7PubMed
80.
Ware Jr JE, Keller SD, Hatoum HT, Kong SX. The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and crossvalidation of scoring algorithms. Med Care 1999; 37 Suppl. 5: MS40–50PubMedCrossRef
81.
Lubeck DP, Yelin E, Katz PP, Roepke L, Wanke L, Buatti M. Responsiveness to change of the SF-36 in RAPOLO, a longitudinal study of rheumatoid arthritis patients treated with etanercept. Value in Health 2001; 4 (2): 63CrossRef
82.
Lubeck DP, Yelin E, Katz PP, Roepke L, Wanke L, Buatti M. The correlation between arthritis specific measures and SF-36 scales in rheumatoid arthritis patients. Value in Health 2001; 4 (2)
83.
Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The MACTAR Patient Preference Disability Questionnaire—an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987; 14 (3): 46–51
84.
Tugwell P, Bombardier C, Buchanan WW. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 59–62PubMedCrossRef
85.
Whalley D, McKenna SP, de Jong Z, van der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol 1997; 36 (8): 884–8PubMedCrossRef
86.
Tijhuis GJ, de Jong Z, Zwinderman AH, et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology 2001; 40 (10): 1112–9PubMedCrossRef
87.
Ditto PH, Druley JA, Moore KA, Danks JH, Smucker WD. Fates worse than death: the role of valued life activities in health-state evaluations. Health Psychol 1996; 15 (5): 332–43PubMedCrossRef
88.
Katz PP, Yelin EH, Lubeck DP, Wanke LA, Buatti MC. Satisfaction with function: what type of function do rheumatoid arthritis patients value most? Arthritis Rheum 2001; 44 Suppl. Abstract 793
89.
Guzman J, Maetzel A, Peloso P, Yeung N, Bombardier C. Disability scores in DMARD trials: What is a clinically important change? Arthritis Rheum 1996; 3 Suppl.: 208
90.
Singh A, Sato R, Wanke L. How much improvement in functioning is considered important by patients with active refractory rheumatoid arthritis. Ann Rheum Dis 2003; 62 Suppl. 2: 108
91.
Kosinski M, Martin R, Henkenius S, Wanke LA, Buatti M. Determining clinically meaningful improvement in SF-36 scale scores for treatment studies in rheumatoid arthritis. Arthritis Rheum 2000; 43 Suppl.: 140
92.
Doyle JJ. Economic and quality-of-life impact of rheumatoid arthritis. Managed Care 2001; 10 Suppl.: 15–18PubMed
93.
Wells G, Anderson J, Beaton D, et al. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol 2001; 28 (2): 452–4PubMed
94.
Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 1993; 20 (3): 557–60PubMed
95.
Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153 (11): 1337–42PubMedCrossRef
96.
Singh G, Sato R, Parasuraman TV, Wanke L, Wyeth Research, Amgen. How much improvement in functional status is considered important by patients with MTX-naïve early rheumatoid arthritis: a comparison with DMARD-refractory patients. Presented at the ACR/ARHP Annual Scientific Meeting 2003, October 24–28, 2003; Florida.
Metadata
Title
Patient-reported outcomes and their role in the assessment of rheumatoid arthritis
Author
Dr Deborah P. Lubeck
Publication date
01-09-2004
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue Special Issue 1/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200422001-00004

Other articles of this Special Issue 1/2004

PharmacoEconomics 1/2004 Go to the issue

EditorialNotes

Foreword

Original Review Article

Pursuit of optimal outcomes in rheumatoid arthritis

Original Review Article

Review of health economics modelling in rheumatoid arthritis

Original Review Article

Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis

Original Review Article

Epidemiology and burden of illness of rheumatoid arthritis